Delineation of TMPRSS2-ERG splice variants in prostate cancer. - Wikidata - wikimedia - TriplyDB

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

http://www.wikidata.org/entity/Q33357287

about

Molecular signaling involving intrinsically disordered proteins in prostate cancer PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer Evaluation of ERG responsive proteome in prostate cancer Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases Molecular genetics of prostate cancer: new prospects for old challenges Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer.Predominance of ERG-negative high-grade prostate cancers in African American men.TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors Oncogenic activation of ERG: A predominant mechanism in prostate cancer.Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1.Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests.Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men.Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men.Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.TMPRSS2-ERG Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological Significance in Prostate Cancer Progression Alternative splicing programs in prostate cancer.ERG protein expression as a biomarker of prostate cancer.New concepts concerning prostate cancer screening.Ets Related Gene and Smad3 Proteins Collaborate to Activate Transforming Growth Factor-Beta Mediated Signaling Pathway in ETS Related Gene-Positive Prostate Cancer Cells.Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers.The oncogene ERG: a key factor in prostate cancer.A computational bioinformatics analysis of gene expression identifies candidate agents for prostate cancer.Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer.Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.ERG oncogene modulates prostaglandin signaling in prostate cancer cells.ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.Androgens Induce Functional CXCR4 through ERG Factor Expression in TMPRSS2-ERG Fusion-Positive Prostate Cancer Cells Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

P2860

Q26747089-21DA7F2F-21DE-41F5-BE23-114E1F105572 Q26752933-6748DCAF-6B85-4255-858C-7BC12BA56392 Q27000495-6D8216DC-52D3-48F4-970B-824C3F9590FB Q33648775-0FFE300E-10B6-4652-BF43-346877C313A9 Q33663401-51483A35-E776-44DC-A78E-54669DDAD493 Q33784622-C4F3EEF1-65CE-4351-8C2D-72617D90C108 Q33822319-DAD37CBD-A62E-48BD-A8C8-FC7332D23F18 Q33871417-5FA8A8DB-78E9-4058-96F0-9A7ADCFE7FD7 Q33909288-44E0F22A-1AF6-4489-9319-5F2E6AE66F74 Q34127462-81EDD625-EFB8-487F-A69F-193D5C48F93C Q34170544-8564E360-94A2-410D-ACEE-7170A2B301ED Q34265721-E43CDC75-1842-4A17-BB8C-930F5409CC29 Q34364174-161534C0-71D5-40E4-A116-D5BBC3A8F62B Q35165354-2F11A16A-ED6D-442D-B4EA-096AD5918E7B Q35631603-999BFD05-B0AE-45A8-AA75-1100C9DB35DC Q35685920-20006C82-BC8F-461F-A2EB-8700A9933584 Q35961920-1E6A4870-D952-4232-81F2-833AD4BE2A8D Q36136098-C3F3A03A-29AA-4095-89FE-5A33B3231D0D Q36435777-55AF5961-362F-4C97-9DC1-853DE3790EA5 Q36437601-F158AA97-173C-4FBF-B703-811FFA5C4A48 Q37139054-9BE18BFD-FAE2-4153-951D-54CD606BE5CF Q37501345-87A35C69-8764-4BF4-BF13-7352EF8B6ECF Q37635618-FBA8C895-B253-4812-BC38-3B2EF2729224 Q38069582-66BBF9CB-5C05-49DE-97C9-29FFE973A58D Q38132132-146C7D91-3569-44E3-8C34-0E73B00D1373 Q38165243-28067F0B-8A83-4D81-8655-B6832EFF67DC Q38220183-E4F727C8-1E15-4F1A-9EFE-0F956DE3B220 Q38300608-CF322066-7AEA-4E60-8387-D4229BE55A50 Q38301071-8B9A1790-A095-48D8-9FE4-FB335A13FAAE Q38444138-AB6E56A7-B2E6-42F5-8582-356E5F3315DF Q38488799-8C97CCD1-A98B-4D56-BB80-4D46A51B98E1 Q38718518-D09DD51D-B963-494F-B707-2D48604E6129 Q38723072-8820FA35-35E3-4E08-98B4-C7B46DB36086 Q38729033-E1CDD469-A281-42FC-91F3-7370F5313B52 Q39616982-5377F797-8937-4447-B091-2A55F43B8A96 Q39666134-0AA3FFF9-C835-4B91-AC69-EE4300811423 Q39690717-2A99C26D-436A-419F-8050-49F4D4278573 Q40028950-6769AA83-D0DD-408A-A1E0-F2A9055E48F4 Q41489983-307D7776-BB9E-4578-8FE8-BFFCB3A9BB3F Q41564129-721BA17D-69D1-4265-93A4-A57C96BD6D75

P2860

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

http://www.wikidata.org/entity/Q33357287

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@ast

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@en

type

label

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@ast

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@en

prefLabel

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@ast

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@en

P1433

Q33357287-F3389637-829A-4E2B-B6B8-9EEFAC56C77E

P1476

Q33357287-C1A8A6F3-B4E0-44A7-9A02-B9D70B36BAA9

P2093

Q33357287-01DCBB50-099A-4531-B75E-B358C61C101B

Q33357287-04BD0E32-F21E-44D6-8C60-65941E746A76

Q33357287-146137BD-ACE2-46EB-8D17-DB5EA3A72E50

Q33357287-17FFEBAD-5666-47FB-A89C-CF8F93ABE7C4

Q33357287-22E88D4A-1933-4BCA-B621-5331436407A2

Q33357287-359465C3-F522-49D2-BEFF-8A1545F66AFC

Q33357287-57D2B738-12C9-4DBF-8149-B17841143418

Q33357287-581B2DC9-5B0B-4D00-A458-93C834CE4B5B

Q33357287-73567A3F-1419-4CA3-93C8-866DCFF18D08

Q33357287-9AB0B140-F202-49BB-BB7C-C0C610AAF7E4

P304

Q33357287-288C83FE-7232-4C57-A703-630959F2D631

P31

Q33357287-4EB66A72-A779-49E8-BF59-5C34C9FB5F5F

P356

Q33357287-80734AF5-601B-4E56-AFCA-CF7D17E5C5F6

P407

Q33357287-63DF6D02-B5BE-4190-AC68-6F83A714037F

P433

Q33357287-A60F9CC8-8599-4BA1-A434-1AAF072B550B

P478

Q33357287-726C00B7-2148-4A90-8D37-7A3802E26751

P50

Q33357287-FD37E04B-178E-4FE2-BB33-A8BAFCE9FADB

P577

Q33357287-CCE09D4F-5EE6-4A69-9CEC-8442F57E223D

P698

Q33357287-73B8E374-52FF-486B-8F21-8C7B2CD76617

P356

1078-0432.CCR-08-0531

P1433

Clinical Cancer Research

P1476

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

@en

P2093

Ahmed Mohamed

http://www.w3.org/2001/XMLSchema#string

Albert Dobi

http://www.w3.org/2001/XMLSchema#string

Atekelt Y Tadase

http://www.w3.org/2001/XMLSchema#string

Chen Sun

http://www.w3.org/2001/XMLSchema#string

Christopher Cook

http://www.w3.org/2001/XMLSchema#string

David G McLeod

http://www.w3.org/2001/XMLSchema#string

Gyorgy Petrovics

http://www.w3.org/2001/XMLSchema#string

Isabell A Sesterhenn

http://www.w3.org/2001/XMLSchema#string

Jennifer Cullen

http://www.w3.org/2001/XMLSchema#string

Lakshmi Ravindranath

http://www.w3.org/2001/XMLSchema#string

P304

4719-4725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-0531

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18676740

http://www.w3.org/2001/XMLSchema#string